Showing 51 to 75 of 122 Results
Page 1 | 2 | 3 | 4 | 5
Gore Receives CE Mark for GORE® Hybrid Vascular Graft
16 August 2012 - More than 2500 Successful Implants for Dialysis Access and Other Vascular Procedures

GORE® Hybrid Vascular Graft Honored as Gold Winner in the 2012 Medical Design Excellence Awards
03 July 2012 - W. L. Gore & Associates (Gore) today announced that the GORE® Hybrid Vascular Graft was awarded Gold Winner in the Implant and Tissue-Replacement Products category of the 2012 Medical Design Excellence Awards (MDEA) competition.

Gore Receives CE Mark for New GORE® EXCLUDER® AAA Endoprosthesis Sizing Options
03 July 2012 - Broader Range of Sizes Now Accommodates More Patient Anatomies

England National Institute for Health Research Stroke Research Network Adopts Gore REDUCE Clinical Study
19 June 2012 - Study Investigates Device Closure of Patent Foramen Ovale (PFO) in Stroke Reduction.


Gore Participates in FDA Circulatory System Devices Advisory Panel Meeting
07 June 2012 - Focus on Safety and Effectiveness of GORE® HELEX® Septal Occluder for Closure of Atrial Septal Defect (ASD)

SVS and Gore Support Increasing Numbers of Women in Vascular Surgery
23 May 2012 - Women’s Leadership to Take Spotlight at the Society for Vascular Surgery 2012 Vascular Annual Meeting

Gore Joins Vascular and Endovascular Leaders in Honoring 2012 Pioneers in Performance in Europe
16 April 2012 - Leading Practitioners and Researchers from Europe Commended for Expanding Treatment Options for At-Risk Patients

First Australian Patients Enrolled in Gore Global Registry for Endovascular Aortic Treatment
20 March 2012 - Royal Prince Alfred Hospital First in Australia

Gore Receives First FDA Approval for Endovascular Repair of Traumatic Aortic Transections
19 January 2012 -

Conformable GORE® TAG® Thoracic Endoprosthesis Designed for Endovascular Repair of the Descending Thoracic Aorta Provides Conformability without Compromise


W. L. GORE & ASSOCIATES NAMED A TOP U.S. WORKPLACE
19 January 2012 - Company has appeared in every listing of the "100 Best Companies to Work For"

Gore Receives FDA Approval for Conformable GORE® TAG® Thoracic Endoprosthesis
16 November 2011 - Durable ePTFE Endoprosthesis Designed for Endovascular Repair of the Descending Thoracic Aorta Provides Conformability without Compromise

Nominees Announced for 2011-2012 Pioneers in Performance Awards for the United States; Online Voting Opens at www.PioneersInPerformance.com
16 November 2011 - Awards Program Sponsored by W. L. Gore & Associates Honors Medical Specialists Advancing Therapy and Improving Patient and Clinical Performance Through Active Collaboration

GORE® Hybrid Vascular Graft Commercially Available in the United States
01 June 2011 - W. L. Gore & Associates today is announcing commercial availability in the US of the GORE® Hybrid Vascular Graft.

First Patient Enrolled in Gore Early TIPS for Ascites Study at Indiana University Hospital
25 April 2011 - Clinical Study to Examine Effects of Early Intervention with Transjugular Intrahepatic Portosystemic Shunt (TIPS) Therapy on Transplant-Free Liver Disease Survival Rates



Gore Receives CE Mark for GORE® PROPATEN® Vascular Graft for Hemodialysis Access
22 February 2011 - Unique Vascular Graft Transcends Mechanical Solutions for Dialysis Access

Gore Announces FDA Approval of Next Evolution of GORE® VIABAHN® Endoprosthesis
17 February 2011 - Lower profile delivery system in the US provides more options for endoluminal bypass

New Clinical Evidence Supporting Efficacy of GORE® PROPATEN® Vascular Graft
19 January 2011 - Jes Lindholt, MD, PhD presented new study data from a Scandinavian clinical trial designed to compare patency rates of the GORE PROPATEN Vascular Graft with standard ePTFE grafts (GORE-TEX® Stretch Vascular Graft).

Gore Announces European Availability of Next Evolution of GORE® VIABAHN® Endoprosthesis
19 January 2011 - Lower profile delivery system in Europe provides more options for endoluminal bypass

Gore Receives Health Canada Approval for Removable GORE® VIABIL® Biliary Endoprosthesis
17 January 2011 - New treatment option now available for benign and malignant biliary strictures

Gore Reports First Patient Treated using GORE® C3 Delivery System for GORE® EXCLUDER® AAA Endoprosthesis
11 January 2011 - New medical innovation repositions the future of endovascular repair for abdominal aortic aneurysm

Gore Launches Study of Early TIPS Therapy for Ascites Patients
01 November 2010 - Experts Call for Fresh Look at Transjugular Intrahepatic Portosystemic Shunt (TIPS) Therapy for Liver Disease Patients


First Patient Implanted in Investigational Study for Self Sealing GORE® ACUSEAL Vascular Graft
12 August 2010 - Study Gauges Benefits for End Stage Renal Disease Patients During Hemodialysis

Doctors in New South Wales and Victoria Become First in Australia to Treat Patients with Aortic Aneurysms Using GORE® DrySeal Sheath
03 August 2010 - Revolutionary Device Delivers Consistent Performance, Better Control, and Minimized Blood Loss During Minimally Invasive Endovascular Procedure

Gore Launches Improved GORE® HELEX Delivery System in Europe
12 July 2010 - W. L. Gore & Associates is pleased to announce the availability of an improved iteration of the GORE® HELEX Septal Occluder. The rollout of the improvement will begin in Europe immediately, and its availability will open up to other markets pending respective regulatory approvals.

Gore Receives CE Mark for Longer Length GORE® VIABAHN® Endoprosthesis
01 July 2010 - Longest stent-graft ever introduced in Europe for SFA endoluminal bypass

Gore Receives CE Mark Approval for Removable GORE® VIABIL® Biliary Endoprosthesis
27 April 2010 - Expanded indication enables stent removal for up to 12 months following implantation for effective treatment of both malignant and benign biliary strictures.

Gore Receives European CE Mark Approval for Next Generation Conformable GORE TAG® Thoracic Endoprosthesis
07 November 2009 - First human implant highlights innovative, conformable design of GORE TAG® Thoracic Endoprosthesis

Gore Announces First Implant of Next Generation Conformable GORE TAG® Thoracic Endoprosthesis in US Clinical Trial for the Treatment of Thoracic Aortic Aneurysms
20 October 2009 - W. L. Gore & Associates (Gore) today announced the first human implants of the next generation Conformable GORE TAG® Thoracic Endoprosthesis for the treatment of thoracic aortic aneurysms (TAAs)

Vascular Surgeons Present Positive Study Results for the GORE PROPATEN® Vascular Graft and Updates to the GORE VIABAHN® Endoprosthesis
17 September 2009 - Physicians report new information at the Society for Vascular Surgery's annual meeting

Gore Receives FDA Approval for Next Generation of Large Diameter GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
21 July 2009 - Improved design now available with lower profile delivery system for use in iliac arteries.

Gore Receives FDA Approval for Next Generation of Large Diameter GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
21 July 2009 - Improved design now available with lower profile delivery system for use in iliac arteries.

Gore Recognizes Physicians as “Pioneers in Performance” for Exceptional Work in the Field of Endovascular Therapy
17 February 2009 - Leading practitioners and researchers from around the world commended for expanding treatment options for at-risk patients

Gore Recognizes Physicians as “Pioneers in Performance” for Exceptional Work in the Field of Endovascular Therapy
17 February 2009 - Leading practitioners and researchers from around the world commended for expanding treatment options for at-risk patients

Gore Receives CE Mark for GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface
14 December 2008 - Gore’s proprietary heparin surface has proven valuable in the clinical treatment of arterial vascular disease.

Rush University Medical Center First to Enroll Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure
11 December 2008 - Multi-national trial to demonstrate safety, effectiveness of GORE HELEX Septal Occluder for PFO closure in patients with a history of cryptogenic stroke

W. L. Gore & Associates Presents New Data and Clinical Updates at Transcatheter Cardiovascular Therapeutics (TCT) Conference 2008
08 October 2008 - Gore continues commitment to clinical research with symposia, ongoing clinical studies and emerging technologies

W. L. Gore & Associates Introduces GORE INFINIT Mesh - A Revolutionary Combination of Material and Structure
01 October 2008 - First and only 100% monofilament PTFE, large-pore knitted surgical mesh designed for long-term patient comfort and quality of life

Gore Announces First Patient Enrolled in Gore REVISE Clinical Study
17 September 2008 - IDE Study to Compare Performance of GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to Percutaneous Transluminal Angioplasty (PTA)

Gore Announces Broadened FDA Indication for GORE VIABAHN® Endoprosthesis for Iliac Occlusive Disease
17 September 2008 - Only Stent-Graft Approved for Treatment of Both Iliac and Superficial Femoral Arteries

Gore Announces First Patient Enrolled in Gore REVISE Clinical Study
17 September 2008 - IDE Study to Compare Performance of GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to Percutaneous Transluminal Angioplasty (PTA)

Gore Announces Broadened FDA Indication for GORE VIABAHN® Endoprosthesis for Iliac Occlusive Disease
17 September 2008 - Only Stent-Graft Approved for Treatment of Both Iliac and Superficial Femoral Arteries

Gore Receives FDA Approval for Modification of GORE VIABAHN® Endoprosthesis
17 September 2008 - Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries.

Gore Receives FDA Approval for Modification of GORE VIABAHN® Endoprosthesis
17 September 2008 - Manufacturing modification of the only stent-graft approved for treatment of both iliac and superficial femoral arteries.

Gore Receives Approval to Market GORE TAG® Thoracic Endoprosthesis in Japan
03 June 2008 - Expedited Clearance Provides Less Invasive Treatment Alternative for Thoracic Aortic Aneurysms

Gore Receives CE Mark for GORE PRECLUDE® Vessel Guard
06 May 2008 - Distinguished seal allows biomaterial to be used across the European Union

Gore Receives Approval from FDA for Unique Patent Foramen Ovale Stroke Study
05 May 2008 - Multinational trial randomizes stroke patients with Patent Foramen Ovale (PFO) to closure with the GORE HELEX Septal Occluder versus medical management

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

First Patient Enrolled in Study Evaluating Performance of Spectranetics Laser Ablation Followed by GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
25 February 2008 - Physician-sponsored study to examine combination therapy for lower limb in-stent restenosis in patients treated for Peripheral Vascular Disease.

VIBRANT Study of GORE VIABAHN® Endoprosthesis Completes Enrollment
01 January 2008 - Randomized Trial to Assess Patency of Covered Stents vs. Nitinol Stents for the Treatment of Vascular Disease

Endovascular Repair of Descending Thoracic Aortic Aneurysm
26 October 2007 - Heart Disease: On Nov 16th, 2007, see a live endovascular repair of a descending thoracic aortic aneurysm with the GORE TAG® Thoracic Endoprosthesis. Michael D. Dake, MD, Professor of Radiology, Internal Medicine, Surgery and Chairman of the UVA Department of Radiology will host this live broadcast.

Endovascular Repair of Descending Thoracic Aortic Aneurysm
25 October 2007 - On November 6, 2007, at 3 pm (EST) surgeons and radiologists from the University of Michigan Health System will perform a descending thoracic aortic aneurysm repair with the GORE TAG® Thoracic Endoprosthesis.

First Patient Enrolled in Study of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for Lower Limb Peripheral Vascular Disease
18 October 2007 - The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.

First Patient Enrolled in Study of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for Lower Limb Peripheral Vascular Disease
18 October 2007 - The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

Gore receives FDA approval for GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions

Gore receives FDA approval for GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

Patient Enrollment Begins in Study on Efficacy of GORE SEAMGUARD® Staple Line Reinforcement for Circular Surgical Staplers
21 May 2007 - More than 2,500 colorectal implants of GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement for circular surgical staplers in past year

GORE PRECLUDE® Vessel Guard Reduces Vascular Injury Risk Following Anterior Vertebral Surgery
07 May 2007 - W. L. Gore & Associates (Gore) announced today the availability of GORE PRECLUDE® Vessel Guard, the first non-biological membrane indicated as a cover for vessels following anterior vertebral surgery.

W. L. Gore & Associates enrolls first patient in study of 45 mm GORE TAG® Thoracic Endoprosthesis
20 February 2007 - W. L. Gore & Associates announced today that the first patient has been enrolled in a US Food and Drug Administration (FDA) approved IDE study for the 45 mm* GORE TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta.

Gore Global Registry for Endovascular Aortic Treatment Reaches 2,500 Enrolled Patients - English

Conformable GORE® TAG® Thoracic Endoprosthesis, GORE® EXCLUDER® AAA Endoprosthesis, GORE® EXCLUDER® Iliac Branch Endoprosthesis, GORE® TAG® Thoracic Endoprosthesis

(47 KB, 2 pages, .pdf)


Gore RELINE MAX Study Patient Enrollment Press Release - English

First Patients Enrolled in the Gore RELINE MAX Clinical Study

(45 KB, 3 pages, .pdf)


Showing 51 to 75 of 122 Results
Page 1 | 2 | 3 | 4 | 5